ERBB2 and neoplasm: Importantly, in preclinical xenograft mouse models of TNBC and HER2-E breast cancer types, PRL was found to cause tumor downstaging as measured by tumor volume/growth and expression of the proliferative marker Ki67 (53, 75, 76).